Disposition of 89561 shares by Sanj Patel of Kiniksa Pharmaceuticals at 1.59 subject to Rule 16b-3
KNSA Stock | USD 19.88 0.78 3.78% |
About 62% of Kiniksa Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Kiniksa Pharmaceuticals suggests that many traders are alarmed. The current market sentiment, together with Kiniksa Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Kiniksa Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Kiniksa |
Filed transaction by Kiniksa Pharmaceuticals Director, Officer: Chairman & Ceo. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Kiniksa Pharmaceuticals Fundamental Analysis
We analyze Kiniksa Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kiniksa Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kiniksa Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
Kiniksa Pharmaceuticals is currently under evaluation in price to sales category among its peers. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Kiniksa Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kiniksa Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Kiniksa Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Kiniksa Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Kiniksa Pharmaceuticals Related Equities
CHRS | Coherus BioSciences | 10.66 | ||||
COGT | Cogent Biosciences | 3.44 | ||||
GOSS | Gossamer Bio | 3.13 | ||||
REPL | Replimune | 2.64 | ||||
SPRO | Spero Therapeutics | 1.16 | ||||
ACLX | Arcellx | 0.81 | ||||
NVCT | Nuvectis Pharma | 0.30 | ||||
GPCR | Structure Therapeutics | 1.15 | ||||
KURA | Kura Oncology | 1.49 | ||||
KRON | Kronos Bio | 1.94 | ||||
VTYX | Ventyx Biosciences | 1.95 | ||||
BOLT | Bolt Biotherapeutics | 2.00 | ||||
NUVL | Nuvalent | 2.21 | ||||
LRMR | Larimar Therapeutics | 3.27 | ||||
DAWN | Day One | 3.81 | ||||
CGEM | Cullinan Oncology | 3.83 | ||||
LYRA | Lyra Therapeutics | 5.26 | ||||
PHAT | Phathom Pharmaceuticals | 5.52 |
Complementary Tools for Kiniksa Stock analysis
When running Kiniksa Pharmaceuticals' price analysis, check to measure Kiniksa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiniksa Pharmaceuticals is operating at the current time. Most of Kiniksa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiniksa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiniksa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiniksa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |